MicroRNA‐218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer
Authors:
- 4 January 2017
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 56 (6) , 1570-1577
Abstract
MicroRNAs have been reported to be associated with chemosensitivity of several types of cancers. However, the underlying molecular mechanisms are poorly understood. In this study, we explored miR‐218 increased the chemosensitivity to cis‐diaminedichloroplatinum treatment of prostate cancer. We found that the expression level of miR‐218 was down‐regulated in the human prostate cancer specimens. Moreover, overexpression of miR‐218 inhibited cell viability, migration, and invasion in PC3 and DU145 cells. Furthermore, we demonstrated that the tumor suppressive role of miR‐218 was mediated by negatively regulating branched‐chain amino acid transaminase 1 (BCAT1) protein expression. Importantly, overexpression of BCAT1 decreased the chemosensitivity to CDDP treatment of PC3 and DU145 cells. Our study is the first to identify the positive role of miR‐218 in chemosensitivity, which will facilitate the development of novel therapeutic strategies for prostate cancer in the future.Keywords
Funding Information
- Advanced Talent Cultivation Projects of Integrated Traditional Chinese and Western Medicine, Shanghai (ZYSNXD012-RC-ZXY013)
- The Third Group of Traditional Chinese Medicine Genres Clinical Inheritance of Shanghai
This publication has 32 references indexed in Scilit:
- Prostate cancerThe Lancet, 2016
- miRNA–mRNA pairs are differently expressed in African American menNature Reviews Urology, 2015
- MiR-200, a new star miRNA in human cancerCancer Letters, 2014
- Expression of Concern: miR‐145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6International Journal of Cancer, 2014
- Receptor-interacting Protein 1 Increases Chemoresistance by Maintaining Inhibitor of Apoptosis Protein Levels and Reducing Reactive Oxygen Species through a microRNA-146a-mediated Catalase PathwayJournal of Biological Chemistry, 2014
- Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized TrialsJournal of Clinical Oncology, 2013
- A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinomaJournal of Clinical Investigation, 2011
- Prostate cancerThe Lancet, 2008
- MicroRNAs Silence Gene Expression by Repressing Protein Expression and/or by Promoting mRNA DecayCold Spring Harbor Symposia on Quantitative Biology, 2006
- Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activationThe Prostate, 2000